Founded in 2016, Ahammune Biosciences operates in Health Tech industry. Initially concentrating on therapeutic solutions for vitiligo, the company has expanded its research and development efforts to ...
Funding stage:
Series A
Last funding:
24/09/2024
Total funding:
$5.00 Mn+
Revenue:
Investors
Employee count:
12
Last 90d
12
Last 90d
Web traffic:
2.05K
2.05K
Last 30d
Last 30d
Ahammune Biosciences: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders56
Latest Filing Date11 Nov 2024- Funding Events17
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Ahammune Biosciences
As of 12 November 2024, Ahammune Biosciences's equity is held by 55 shareholders, with the top three being Krishnamurthy Natarajan, Parul Ganju, and pi Ventures Fund II.
Krishnamurthy Natarajan holds the largest stake in Ahammune Biosciences at 24.4% as of 12 November 2024.
As of 12 November 2024, founders collectively hold 46.0% equity in Ahammune Biosciences.
As of 12 November 2024, investors collectively hold 42.5% equity in Ahammune Biosciences.
Ahammune Biosciences's ESOP pool stands at 8.1% of total equity as of 12 November 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links